A detailed history of Aldebaran Financial Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Aldebaran Financial Inc. holds 2,360 shares of ABBV stock, worth $432,068. This represents 0.58% of its overall portfolio holdings.

Number of Shares
2,360
Holding current value
$432,068
% of portfolio
0.58%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 21, 2024

BUY
$163.84 - $199.33 $386,662 - $470,418
2,360 New
2,360 $466,000
Q1 2024

May 13, 2024

BUY
$159.82 - $182.1 $175,802 - $200,310
1,100 New
1,100 $200,000
Q2 2022

Aug 01, 2022

SELL
$137.62 - $174.96 $953,018 - $1.21 Million
-6,925 Reduced 70.13%
2,950 $450,000
Q1 2022

Apr 18, 2022

SELL
$131.98 - $163.75 $16,497 - $20,468
-125 Reduced 1.25%
9,875 $1.6 Million
Q4 2021

Feb 16, 2022

BUY
$107.43 - $135.93 $5,478 - $6,932
51 Added 0.51%
10,000 $1.35 Million
Q3 2021

Oct 21, 2021

BUY
$106.4 - $120.78 $23,088 - $26,209
217 Added 2.23%
9,949 $1.07 Million
Q2 2021

Jul 16, 2021

BUY
$105.21 - $117.21 $113,732 - $126,704
1,081 Added 12.5%
9,732 $1.11 Million
Q1 2021

May 03, 2021

BUY
$102.3 - $112.62 $30,690 - $33,786
300 Added 3.59%
8,651 $936,000
Q4 2020

Feb 05, 2021

BUY
$80.49 - $108.67 $241,550 - $326,118
3,001 Added 56.09%
8,351 $895,000
Q3 2020

Oct 19, 2020

BUY
$85.91 - $100.83 $20,188 - $23,695
235 Added 4.59%
5,350 $469,000
Q2 2020

Jul 20, 2020

SELL
$73.37 - $98.18 $470,301 - $629,333
-6,410 Reduced 55.62%
5,115 $502,000
Q1 2020

Apr 24, 2020

BUY
$64.5 - $97.79 $240,262 - $364,267
3,725 Added 47.76%
11,525 $878,000
Q4 2019

Feb 10, 2020

BUY
$72.13 - $90.25 $562,614 - $703,950
7,800 New
7,800 $691,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $324B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Aldebaran Financial Inc. Portfolio

Follow Aldebaran Financial Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aldebaran Financial Inc., based on Form 13F filings with the SEC.

News

Stay updated on Aldebaran Financial Inc. with notifications on news.